Novavax, Inc.

NVAX · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Revenue$70,445$239,240$666,655$88,311
% Growth-70.6%-64.1%654.9%
Cost of Goods Sold$21,496$14,225$14,115$36,669
Gross Profit$48,949$225,015$652,540$51,642
% Margin69.5%94.1%97.9%58.5%
R&D Expenses$98,274$77,633$88,937$104,380
G&A Expenses$0$0$0$0
SG&A Expenses$31,655$40,612$48,090$78,342
Sales & Mktg Exp.$0$0$0$0
Other Operating Expenses$97,038$1,100$0$0
Operating Expenses$226,967$119,345$137,027$182,722
Operating Income-$178,018$105,670$515,513-$131,080
% Margin-252.7%44.2%77.3%-148.4%
Other Income/Exp. Net-$25,018$1,784$4,333$57,499
Pre-Tax Income-$203,036$107,454$519,846-$73,581
Tax Expense-$657$946$1,200$7,449
Net Income-$202,379$106,508$518,646-$81,030
% Margin-287.3%44.5%77.8%-91.8%
EPS-1.250.663.22-0.51
% Growth-289.4%-79.5%731.4%
EPS Diluted-1.250.62.93-0.51
Weighted Avg Shares Out162,353162,019161,049160,241
Weighted Avg Shares Out Dil162,353177,215177,625160,241
Supplemental Information
Interest Income$0$0$0$0
Interest Expense$5,482$5,518$5,723$7,585
Depreciation & Amortization$6,585$7,563$8,340$12,517
EBITDA-$190,969$120,535$533,909-$53,479
% Margin-271.1%50.4%80.1%-60.6%